News

ivWatch Partners with National Infusion Center Association (NICA)

ivWatch, LLC, the IV safety company, today announced that it has partnered with the National Infusion Center Association (NICA), an independent, nonprofit trade association and accrediting body dedicated to representing ambulatory outpatient care settings where provider-administered biologics and specialty medications are prepared and administered.

In alignment, ivWatch and NICA are partnering with an emphasis on providing innovative and accessible solutions to freestanding infusion centers and their patients. The proprietary patient monitoring technology from ivWatch allows patients to have continuous IV site monitoring during infusions in the comfort and convenience of an outpatient setting.

“NICA has been the nation’s voice for independent infusion centers for more than a decade, overcoming countless barriers to care and access obstacles on behalf of patients and dedicated to ensuring that the nation’s infusion centers remain a safe, efficient, and cost-effective means of receiving consistent, high-quality care,” notes Brian Nyquist, MPH, NICA President and CEO. “We are excited to have ivWatch on board in 2024 as our trusted partner in helping our industry remain on the cutting edge of patient safety innovation.”

“Infusion centers are on the frontlines of IV patient safety, so this partnership is a natural fit,” says Erin Wendell, chief marketing officer at ivWatch. “It is also a perfect opportunity to work with this fast-growing segment of the healthcare industry in advocating for the increased adoption that a monitoring technology can play in reducing the severity of IV injuries while also mitigating the liability risks associated with IV extravasation and infiltration.”

This partnership comes at a monumental time of global adoption for ivWatch, as the company expands its reach to patients in all care areas that provide essential infusions. The company recently filed for 510(k) clearance for iron-based infusions to better protect patients not only from IV injuries but also the specific lifelong effects of irreversible skin staining that occurs with iron extravasations.

NICA and ivWatch will collaborate on several educational webinars relevant to infusion centers, including the recognition and interventions of early stages of IV extravasations to help promote safer delivery of IV therapy. The company will also exhibit at NICA’s annual conference on June 21-22, 2024, at the MGM Grand in Las Vegas in Booth 207. ivWatch will be a key participant at the exclusive NICA Infusion Center of Excellence (NICE) Experience, which provides an insider look at the ideal infusion center model. Products and technologies that improve patient care and promote patient safety will be displayed prominently. The event will provide a firsthand immersive experience for clinicians, administrators, managers, and owners.

 

Learn more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep